Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041056 | 1.00 | ANPEP (0.49) | ANPEPLAP3MMP1MMP3GRN | |
| SCHEMBL12621365 | 0.89 | ANPEP (0.47) | ANPEPLAP3MMP1MMP3 | |
| SCHEMBL31435784 | 0.87 | BTN3A1 (0.45) | ANPEPLAP3MMP1MMP3ALDH1A1 | |
| SCHEMBL30751467 | 0.87 | BTN3A1 (0.45) | ANPEPLAP3MMP1MMP3BCL2L1 | |
| SCHEMBL12621368 | 0.85 | ELANE (0.50) | — | |
| SCHEMBL12654939 | 0.83 | ANPEP (0.41) | ANPEPLAP3MMP1MMP3ALDH1A1 | |
| SCHEMBL20819161 | 0.83 | GGH (0.40) | ANPEPLAP3MME | |
| SCHEMBL20819159 | 0.83 | GGH (0.40) | ANPEPLAP3MME | |
| SCHEMBL23859849 | 0.82 | ANPEP (0.48) | ANPEPLAP3MME | |
| SCHEMBL19206430 | 0.82 | ANPEP (0.48) | ANPEPLAP3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2016035006-A1 | NOVEL NUCLEOTIDE ANALOGS, PROCESS FOR THE PREPARATION OF SOFOSBUVIR AND ITS ANALOGS, NOVEL FORMS OF SOFOSBUVIR AND SOLID DISPERSION OF SOFOSBUVIR | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | ANPEP 517/4885LAP3 1312/4885MMP1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.